-+ 0.00%
-+ 0.00%
-+ 0.00%

ELICIO THERAPEUTICS ANNOUNCES ACTIVATION OF THE INVESTIGATOR-INITIATED PHASE 1 STUDY OF NEOADJUVANT ELI-002 7P FOR PANCREATIC DUCTAL ADENOCARCINOMA

Reuters·08/10/2026 12:00:03

Please log in to view news